Skip to main content
Log in

Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren

Highlights des ASCO-Meetings 2014

Main results of studies on primary therapy of head and neck squamous cell carcinoma

Highlights of the ASCO Meeting 2014

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

An Erratum to this article was published on 05 October 2015

Zusammenfassung

Bei der primären Radiochemotherapie (RCT) von lokal fortgeschrittenen Kopf-Hals-Tumoren stehen sich 2 mögliche Vorgehensweisen gegenüber und sind Gegenstand der aktuellen Studien: die konkomitante und die sequenzielle RCT. Beim jährlichen Treffen der American Society of Clinical Oncology (ASCO) wurden auch 2014 Studien zur primären, nichtchirurgischen Therapie lokal fortgeschrittener Kopf-Hals-Tumoren vorgestellt. Eine Auswahl wird in diesem Beitrag besprochen, u. a. wird auf die cisplatinbasierte RCT als Standardtherapie für lokal fortgeschrittene Kopf-Hals-Tumoren, alternative Substanzen für Cisplatin, die Kombination mit Targettherapeutika, den Einsatz des epidermalen Wachstumsfaktorrezeptor(EGFR)-Antikörpers Cetuximab und auf den Vergleich der sequenziellen Therapie mit der konkomitanten RCT eingegangen. Darunter wird auch eine erstmalig vollständig rekrutierte Phase-III-Studie zur Induktionschemotherapie vorgestellt.

Abstract

The two available options for primary radiochemotherapy (RCT) of locally advanced head and neck squamous cell carcinoma are discussed in the current study: concomitant and sequential RCT. At the annual meeting of the American Society of Clinical Oncology (ASCO) 2014, results of current trials on the primary nonsurgical therapy of locally advanced head and neck tumors were presented. A selection of the most important trials will be summarized in this article. Studies including cisplatin-based RCT as standard therapy for locally advanced head and neck tumors, alternatives for cisplatin, combination with targeted therapy, application of the epidermal growth factor receptor (EGFR) antibody cetuximab and the comparison of concomitant and sequential RCT are discussed. The first completely recruited phase III trial comparing concomitant and sequential RCT will also be presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Adkins D, Ley J, Nussenbaum B et al (2011) Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 29(Suppl):abstr 5560

    Google Scholar 

  2. Ali EM, Hasan E, Elyamany A et al (2014) Gemcitabine versus cisplatin concomitant with radiotherapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 32(Suppl):abstr e17039

    Article  Google Scholar 

  3. Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29(Suppl):abstr 5500

    Google Scholar 

  4. Barni S, Coinu A, Borgonovo K et al (2014) Cisplatin versus Cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: a meta-analysis of published trials. J Clin Oncol 32:5s (Suppl):abstr 6014

  5. Bauman JE, Gooding WE, Clump DA (2014) Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAB) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). J Clin Oncol 32:5s (Suppl):abstr TPS6104

  6. Bonner JA, Harari PM, Giralt J (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28

    Article  CAS  PubMed  Google Scholar 

  7. Budach W, Boelke E, Kammers K et al (2014) Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy as treatment of unresected locally advanced head and neck cancer squamous cell cancer (HNSCC): a meta-analysis of randomized trials. J Clin Oncol 32:5s (Suppl):abstr 6012

  8. Cmelak A, Li S, Marur S et al (2014) E1308: reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). J Clin Oncol 32:5s (Suppl):abstr LBA6006

  9. Cohen E, Karrison T, Kocherginsky M (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30(Suppl):abstr 5500

    Google Scholar 

  10. Dietz A, Flentje M, Hagen R et al (2014) Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-Fluorouracil (f) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): first results of the phase II randomized DeLOS-II study. J Clin Oncol 32:5s (Suppl):abstr 6016

  11. Forastiere A, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  CAS  PubMed  Google Scholar 

  12. Forastiere A, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845–852

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Ghi MG, Paccagnella A, Ferrari D et al (2014) Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 32:5s (Suppl):abstr 6004

  14. Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14(3):257–264

    Article  CAS  PubMed  Google Scholar 

  15. Hitt R, Grau JJ, López-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25(1):216–225

    Article  CAS  PubMed  Google Scholar 

  16. Knecht R (2014) Induction chemotherapy (ICT) followed by radiochemotherapy (RCT) versus radiochemotherapy alone as treatment in advanced laryngeal (LC)/hypopharyngeal cancer (HC): phase IIb. J Clin Oncol 32:5s (Suppl):abstr 6015

  17. Ley JC, Nussenbaum B, Diaz J et al (2014) Comparison of clinical primary tumor site (PTS) response to induction chemotherapy (IC) with APF (nab-paclitaxel, cisplatin, and 5-FU) or APF plus cetuximab (APF + Cetux) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 32:5s (Suppl):abstr 6013

  18. Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12(2):153–159

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Paccagnella A, Ghi MG, Loreggian L et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21:1515–1522

    Article  CAS  PubMed  Google Scholar 

  20. Pignon JP, Maître A le, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14

    Article  PubMed  Google Scholar 

  21. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin und fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

    Article  CAS  PubMed  Google Scholar 

  22. Rosenthal I, Harari PM, Giralt J (2014) Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 32:5s (Suppl):abstr 6001

  23. Savvides P, Ayyappan S, Yao M et al (2014) Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 32:5s (Suppl):abstr 6070

  24. Vermorken JB, Remenar E, Herpen C van et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704

    Article  CAS  PubMed  Google Scholar 

  25. Weidhaas JB, Harris J, Axelrod R et al (2014) The KRAS-variant and cetuximab response in RTOG 0522. J Clin Oncol 32:5s (Suppl):abstr 6000

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. A. Gliese und C.-J. Busch geben an, dass kein Interessenkonflikt besteht. R. Knecht ist Mitglied des Advisory Boards von Merck Serono, Sanofi Aventis, Boehringer Ingelheim und Bayer Healthcare Leverkusen. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Knecht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gliese, A., Busch, CJ. & Knecht, R. Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren. HNO 62, 781–786 (2014). https://doi.org/10.1007/s00106-014-2926-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-014-2926-1

Schlüsselwörter

Keywords

Navigation